Latest news with #cardiaccare
CTV News
7 days ago
- Health
- CTV News
Chinook Regional Hospital Foundation announces Hearts and Health Classic golf tournament
The Chinook Regional Hospital Foundation has announced its new golf tournament. The foundation will debut its Hearts and Health Classic on Aug. 26, 2026, at Paradise Canyon. The inaugural tournament will benefit the Bringing Hearts Home campaign to improve access to life-saving cardiac care throughout southern Alberta. The classic follows the conclusion of the Val Matteotti Italian Open last year, which raised nearly $2 million in its 30-year history. The foundation says money raised will go right back to helping those in the community. 'The support of volunteers and community members and donors and sponsors and just the effort that it takes to deliver a great day is so meaningful because every dollar contributed helps us care for every generation by addressing urgent needs across all age groups,' said Oliver Twizell, Chinook Regional Hospital Foundation development director. The foundation is currently recruiting volunteer committee members to help shape the new event.
Forbes
11-07-2025
- Business
- Forbes
Aligning Personal Purpose With Strategic Vision To Grow Your Business
As AliveCor CEO, Priya Abani is leading the drive to patient-centric remote cardiological care. After a career in big tech and a personal loss that reshaped my perspective, I set out to apply my skills where they could make the most impact: healthcare. Now, as CEO of an AI-driven cardiac care startup, I'm leading a mission to transform cardiac care. Here's how aligning personal purpose with strategic vision can fuel innovation, unlock partnerships and drive meaningful growth in the technology industry. Let your personal mission fuel your business vision. From an early age, I had a passion for math and logic. My father was the first person in my life to notice this spark and nurture it, teaching me BASIC when I was just 12 years old. More than a 'basic' lesson in computer science, this early introduction was formative, igniting my curiosity about complex systems, love for solving problems through technology and confidence in navigating a world increasingly shaped by data. That same confidence and foundational curiosity my father helped instill, combined with an M.B.A. in entrepreneurship from Babson College, landed me in leadership roles at Intel and Amazon. I've held a deep interest in the fundamentals of healthcare and care delivery, so when the opportunity to lead AliveCor came, and I learned about the life-saving potential of their solutions, I felt an unshakeable pull to pursue it. Today, as the proud CEO of AliveCor, I'm honored to lead the charge in redefining AI's role in cardiology. If you're a business leader looking to channel a personal mission into professional impact, start by asking yourself: What problems in the world can I have the most impact on? What problems in the world keep me up at night? How could my expertise, connections or team be used to address them? Your personal story doesn't have to be dramatic to be powerful—just authentic. Reflect on formative moments in your life and identify patterns in what drives you. Then, consider how those insights can guide your leadership decisions, product strategy or company culture. Several tech and business leaders have built health-focused ventures inspired by personal experiences. Purpose grounded in lived experience is a strategic advantage. Lean on your R&D teams to expand impact. AliveCor began in 2011 when founder Dr. David Albert reimagined what heart health could look like outside the clinic with the creation of the first FDA-cleared portable ECG device. Building on that breakthrough, AliveCor continued to break barriers in cardiac care, with each innovation marking a step forward in making heart health more personal, portable and proactive. Today, we're expanding beyond consumer devices and have a commercial presence in over 40 countries, scaling our impact to people worldwide. But we wouldn't have been able to make these strides without our dedicated research and development (R&D) and product teams. To expand your company's impact, make sure your R&D and product teams are customer-obsessed and conduct extensive research to ensure that your solutions are created with the end user in mind. Prioritize your users through intuitive design and user experience that makes your products and services more powerful, efficient and engaging. Innovation should be grounded in reality. That means designing for real-life settings: noisy data, busy workflows and tough edge cases. Don't build tech for show—build it to solve real problems. Innovation alone isn't enough—partnerships are key. Partnerships are key to extending influence. Reaching our hand across the aisle, we've forged strategic collaborations that have critically advanced our mission. In our case, relationships with health systems, biopharma giants and payers have helped integrate AliveCor's technology into the broader healthcare ecosystem. If you're a tech leader looking to form meaningful partnerships, start by clarifying your core mission and values, then look for organizations that share them. Ask potential partners: What does success look like for you? Where do our visions align? What gaps could we help each other fill? Seek relationships where there's mutual benefit, not just brand prestige or reach. Some of our most productive collaborations started with a shared challenge and a willingness to co-create, not just transact. Conclusion In a world defined by disruption, staying grounded in purpose is one of the most powerful strategies for sustainable growth. Whether you're building new technology or rethinking existing systems, let your personal mission serve as your compass. Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
RNZ News
08-07-2025
- Health
- RNZ News
Anti-red tape bill a health risk, doctors say
Bill architect David Seymour insists it is about ensuring rules are actually justified and calls critics are "woefully misinformed". Photo: RNZ / Mark Papalii Deputy Prime Minister David Seymour insists his bill - the party's fourth attempt to get similar legislation passed - is about ensuring rules are actually justified and calls critics are "woefully misinformed". Hokianga farmer Tokowhati Piripi finally had his long-awaited heart surgery two weeks ago at Auckland City Hospital. He actually needed a second operation within 24 hours after a sudden life-threatening bleed, but is now recovering well. Teina Piripi, who once feared her husband would die on the waiting list, said the care he had received had been "incredible" - but the outcome for the vast majority of Māori was not so good. "There is no way of explaining why Māori receiving cardiac care survive 50 percent less than non Māori." Teina Piripi - who works as a Kaiāwhina (Māori health support worker) in Northland - said the problem with the Regulatory Standards Bill was that it claimed everyone was "equal under the law", but that was not supported by the facts. "All those laws were used to dispossess us and disenfranchise us from our land, from our ways of life, from our language. "They know this. So it is not equitable, and we don't receive equal care for our health and well-being, otherwise we wouldn't die seven years earlier than everyone else." The 2023 coalition agreement between ACT, National and New Zealand First included a pledge to pass a Regulatory Standards Act "as soon as practical" - but when passed, the bill will not be binding. It lays out a set of principles which law-makers, ministries and agencies must consider when looking at changes to regulation: people's freedom of choice and private property rights should not be unduly affected and there should be fair compensation. The Association of Salaried Medical Specialists - which represents the 6500 senior doctors and dentists working in public hospitals - was one of scores of health organisations, which made submissions against the bill. Senior policy and research advisor Virginia Mills said the RSB was about upholding individual rights - but that would not lead to equitable outcomes, especially in health and particularly for Māori. "It includes this formal principle that 'everyone is equal under the law', which on the surface sounds okay, but is actually quite a loaded principle because when it comes to health. "People have got different needs and require different treatments, and we know that treating everyone the same won't lead to the same outcomes." The RSB also saw regulation as "a negative hindrance" - red tape that needed cutting, she said. "But if you were to deregulate the health workforce for example, that could mean lowering the standard of education or experience or skills to do the job, which could lead directly to patient harm." Seymour - who is also associate health minister - said the RSB's aim was not deregulation. "These comments are woefully misinformed. "The bill does not have an emphasis on deregulation, so that is a false assumption from the get go. "The bill does have an emphasis on transparency and justification when rules are made." The proposed new law would have a Regulatory Standards Board to consider how legislation measures up to its principles, with members appointed by the Minister for Regulation - currently Seymour. Psychiatrist Giles Newton-Howes said he and his colleagues had major concerns about what such transparency meant for health services. "Who makes the decisions about what regulations are appropriate or not and how that is measured? "And if that is done in economic terms, we're fundamentally missing the point. "You're trying to monetise health, and you can't do that." In its submission on the RSB, the Royal Australian and New Zealand College of Psychiatrists said it was dangerous to allow two people (the Regulatory Standards Minister and the Attorney-General) to decide whether wider consultation was needed. "Without legislative expectation to consult with those who hold the most experience in particular spaces, such as psychiatry, we expose ourselves to the mercy of ministerial appointments and ideological frameworks that may not reflect evidence based best practice in health." The submission also noted a "one size fits all model" did not work in complex spaces, such as health and addiction, especially for those who were "persistently harmed by unconscious bias, systemic racism, and social drivers of intergenerational trauma". Newton-Howes said if New Zealanders were truly "equal under the law" in terms of health outcomes, some groups should be receiving more resources than they were. "You can pretty much name any objective you like and we're not [equal under the law], because we're under-serving people in poverty, people in rural areas, Māori and Pacific people, and particularly for mental health." Nurses Organisation chief executive Paul Goulter feared the bill would open the door to further privatisation of healthcare because it favoured business interests. "You get a tension between that collective right to a quality public health system and the private property owning rights. "And this bill takes you into the private property owning rights having dominance over the collective right to a quality public health system." Public health and legal experts have also warned of a potential "chilling effect" on public health measures . They point out that under the bill's "takings or impairment principle", it would allow commercial interests (such as the tobacco and alcohol industries or big polluters), to seek compensation from taxpayers if future legislation caused them to lose money. Seymour has denied the legislation could be weaponised by business interests. "The bill does not anywhere mention, preserving the right to make a profit, so such an objection could never be raised. I would be very happy to sit down with these people and address their concerns, because it appears to me that they have not properly understood the bill before criticising it." The RSB made it clear it created no new legal rights or obligations enforceable through the courts. Furthermore, there was provision under the bill to "constrain" someone's liberties in order to secure the same liberty for others, Seymour said. "That is how you would justify a restriction on polluting the air or water that other people breathe or swim, for example. "If people feel their proposals will not withstand scrutiny, the answer is not to oppose scrutiny but come up with better proposals." However, leading medical oncologist Associate Professor George Laking, Māori Clinical Director at Auckland University's Centre for Cancer Research, remained sceptical. "If you look at the history of environmental catastrophes around the world, they're all carried by people who don't have power to affect the political process, and those are the ones who end up with trash and pollution and the knock on health effects of that. "So sure, there may be provision to deal with pollution under the RSB, but it's much more likely to be dealt with if it irritates someone who's wealthy." There was a risk the "broad brush" legislation with its narrow focus on economic measures could be used - for instance - to change Pharmac's current remit of focusing on patient outcomes, he said. "Of course efficiency is important but what I object to is this elevation of efficiency as the 'be all and end all'. It's not as simple as that." He was disturbed by Seymour's tongue-in-cheek remarks following a speech to the Adam Smith Institute in London last month, in which he credited smokers with saving governmental balance sheets by paying lots of excise tax and not claiming a pension. "This Minister's clearly not interested in health outcomes if he's going to jokingly refer to people who smoke as so-called 'fiscal heroes'. He's much more interested in fiscal outcomes than health outcomes." Parliament's Finance and Expenditure Select Committee is meeting all this week to hear submissions and is due to report back in November. Meanwhile, Teina Piripi was looking forward to taking her husband home to Northland ahead of the birth of their new mokopuna next month. Several times a day, while visiting him at Auckland City Hospital, she has walked past a plaque commemorating the fact the land for it was donated by Ngāti Whātua chief Āpihai Te Kawau in 1847. "Most of our hospitals in this country are built on Māori land - and why? "It's because Māori care about people. It's innate to our understanding. "This bill denies history and the present and the breaches and inequities that come from denying that racism exists." Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
National Post
07-07-2025
- Health
- National Post
CorFlow Therapeutics Announces FDA Approval of the MOCA-II IDE Pivotal Trial to Validate a Novel Heart Attack Care Technology
Article content BAAR, Switzerland — CorFlow Therapeutics AG (CorFlow), a pioneering company in the field of cardiac care targeting microvascular disease, today announced that the U.S. Food & Drug Administration (FDA) has approved the company's technology for investigational device exemption (IDE), which allows the pivotal clinical trial to begin at U.S. hospitals. CorFlow will now prepare these clinical trial sites to receive CorFlow systems, undergo training and begin enrolling patients being treated for heart attacks. Article content The IDE Pivotal Trial, MOCA-II, is intended to prospectively validate the diagnostic accuracy of the proprietary CorFlow CoFl system in determining the presence or absence of microvsacular obstruction (MVO) during a primary PCI procedure. The primary endpoint compares the CoFI diagnostic reading to a reference standard of diagnosis by a cardiac MRI scan. The trial is approved to enroll over 200 STEMI patients at prestigious research institutions in both the United States and Europe. Article content Article content Having successfully completed the first-in-human MOCA-I trial in 2024, the MOCA-II study is the next critical step to bringing this unique technology into the hands of interventional cardiologists globally for the rapid diagnosis of MVO in heart attack patients. This in turn can enable new treatments and care pathways to the large MVO patient population with high rates of adverse clinical outcomes today. The CorFlow technology is designed to both diagnose MVO, plus serve as a localized drug delivery system for diagnostic and therapeutic agents, which is being researched independently. Article content According to the US government Centers for Disease Control and Prevention, someone has a heart attack every 30 seconds in the USA, with about 800,000 cases reported annually in the country. Incidence and prevalence are similarly high in Europe. More than half of STEMI heart attack patients are shown to have MVO, and previous research has demonstrated that the presence of MVO is a major driver of adverse events. Currently, there are no technologies approved to diagnose MVO during an acute coronary intervention, and there are no approved therapeutic devices that specifically address MVO in the United States or Europe. Heart attacks and related heart disease remains a leading cause of death and disability worldwide. Article content Paul Mead, CEO of CorFlow, said, 'The long history of interventional cardiology and heart attack care breakthroughs – going back over 100 years – is one of the great success stories of medical care progress, but the pioneers and luminaries of the field all agree that the work is unfinished. The majority of acute STEMI survivors have MVO, and current outcomes for these patients are shockingly poor. We aim to bring this issue to light and show you can do something about it. This milestone brings us all one step closer to delivering on the promise to improving care for these people where we know we can do better.' Article content MOCA-II is being led by world-renowned experts in heart attack care, Dr. Timothy Henry at The Christ Hospital in Cincinnati, Ohio (United States) and Professor Marco Valgimigli at Cardiocentro Ticino Institute, Lugano (Switzerland), who collectively have been published in over 1,000 peer-reviewed manuscripts in cardiovascular research. Article content Dr. Tim Henry said, 'As an interventional cardiologist involved for decades in managing and researching STEMI patients, I am excited to get going on this pivotal trial with technology that could make such a significant impact to the outcome of our patients. I believe strongly that knowing with high confidence who has MVO at the point of care during a primary PCI procedure can make an immediate difference in how we manage our patients.' Professor Valgimigli added, 'Having played a significant part in MOCA-I first in human trial, I am thrilled to see the second-generation technology now available for the pivotal trial and am looking forward to contributing further to the scientific understanding of MVO in real time. While the medical community has diverse opinions on how to treat these patients, there is no question that proper diagnosis is the first step we need. I am optimistic that getting the CorFlow technology approved for everyday use by our peer interventional cardiologists can help move the field forward.' Article content About CorFlow Therapeutics: Headquartered in Baar, Switzerland, with subsidiary operations in both Italy and the United States. The company is venture capital funded with an international VC firm syndicate, most recently with a Series B financing round announced in September 2024. CorFlow aspires to be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow anywhere in the human body where a critical need exists. Working in close partnership with scientists from the University of Bern, ETH Zurich and the University Hospital Zurich, in a collaboration funded by the Swiss Innovation Agency (Innosuisse), CorFlow continues to explore applications for the unique patented technology. Article content Article content Article content
Malay Mail
23-06-2025
- Health
- Malay Mail
Bangkok Heart Hospital Launches Next-Generation Minimally Invasive Cardiac Surgery Program with MICS CABG and Totally 3D Endoscopic Valve Surgery
MISC CABG Operation BANGKOK, THAILAND - Media OutReach Newswire – 23 June 2025 - Bangkok Heart Hospital is ushering in a new era of cardiac innovation with the introduction of two advanced surgical techniques:and. This marks a strategic milestone as the hospital, Thailand's first private heart center, celebrates its 20th anniversary with a renewed commitment to precision medicine and regional leadership in minimally invasive cardiac treated over a million patients with complex heart conditions, the hospital now offers next-generation procedures that minimize trauma, recovery time, and post-operative risks while delivering outcomes comparable to traditional open-heart surgery."We've proudly pioneered off-pump CABG as our signature approach, and today, we take another leap forward," said. "By advancing into minimally invasive heart surgery, we are improving patients' quality of life while highlighting Bangkok's role as a destination for advanced cardiac care., led by cardiovascular surgeon, allows surgeons to perform bypass procedures through a 7–10 cm incision between the ribs, avoiding the need to open the chest or use a heart-lung machine. This approach is ideal for patients with isolated left coronary artery disease and offers faster recovery with fewer complications., developed by, repairs or replaces valves through a 4–5 cm incision using high-resolution 3D imaging. Suitable for mitral and aortic valve procedures and even congenital defects like atrial septal defect (ASD), the technique improves surgical precision and accelerates recovery."This technology lets us operate in tight spaces without disturbing major structures," said Dr. Paradorn. "Patients recover faster with outcomes equivalent to traditional surgery."Bangkok Heart Hospital has invested in hybrid operating rooms (hybrid ORs), specialized surgical teams trained overseas, and fully integrated support systems for Thai, expat, and international patients. As part of BDMS, the hospital plans to expand MICS capabilities to other facilities in the with Thailand's strategy to become a global medical hub, this milestone positions Bangkok as a leading destination for advanced, minimally invasive heart treatment in #BangkokHeartHospital The issuer is solely responsible for the content of this announcement.
